Protagenic Therapeutics (PTIX) — Cash Flow Quality Index

Latest as of December 2025: -0.07x

Protagenic Therapeutics (PTIX) has a Cash Flow Quality Index of -0.07x as of December 2025. Operating cash flow of $-410.42K is below net income of $5.83 Million, suggesting accrual-heavy earnings not yet converted to cash. Also explore Protagenic Therapeutics (PTIX) total assets for the complete picture of this company's asset base.

Cash Flow Quality Index

-0.07x
Operating CF / Net Income

Operating Cash Flow

$-410.42K
USD

Net Income

$5.83 Million
USD

Data as of

Dec 2025
Most recent filing

Protagenic Therapeutics Cash Flow Quality Index (1998–2006)

Historical Cash Flow Quality Index for Protagenic Therapeutics across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check PTIX tangible net assets ratio to evaluate the tangible quality of the company's equity base.

Annual Cash Flow Quality Index for Protagenic Therapeutics (1998–2006)

Year-by-year earnings quality comparison for Protagenic Therapeutics. For live market cap and the full company financial profile, see Protagenic Therapeutics (PTIX) market capitalisation.

Year Quality Index Operating CF (USD) Net Income YoY Change
2006 1.38x $931.00K $677.00K ▼ -86.8%
2001 10.44x $1.50 Million $144.00K ▲ +238.2%
2000 3.09x $3.51 Million $1.14 Million ▲ +561.1%
1998 -0.67x $-434.00K $648.00K
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.